Archive: Company News
Company News: Pan Cancer T B.V. Appoints Seasoned Entrepreneurs and Executives to its Supervisory Board and Elects its Chairman
– John Tchelingerian, PhD (Chair), Dharminder Singh Chahal and Prof. Dr. Chris Bangma to form Supervisory Board
Pan Cancer T B.V., a biotech company discovering and developing first-in-class T-cell receptor (TCR) T-cell therapy for hard-to-treat solid tumors, today announced the appointment of John Tchelingerian, PhD, as Chairman and of Dharminder Singh Chahal and Prof. Dr. Chris Bangma as members of the Supervisory Board. This marks an important step in the development of the Company and is aligned with its ambitious goals regarding financing, deal-making, and cancer immunotherapy.
Company News: Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program
— Publication of international research group in Frontiers in Cardiovascular Medicine confirms key role of miR-132 in cardiovascular diseases
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Company News: Allero Therapeutics´ Immunotherapy Approach in Food-Induced Immune Disorders Validated by Two Peer-Reviewed Publications
– Promising data in celiac disease patients
– Specific OroMucosal ImmunoTherapy concept supported by animal data
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced the publication of two studies further detailing and validating its approach to combat food-induced immune disorders with its SOMIT (Specific OroMucosal ImmunoTherapy) platform technology.
Company News: Neonatal Diagnostics Company InfanDx Closesx Interim Financing Round
— Funding allows further advancement of lead product and achievement of key near-term milestones
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the closing of an interim financing round involving both existing and new investors. The proceeds from this funding round are expected to provide the financial runway to achieve certain value-creating near-term milestones in clinical biomarker research for the Company’s lead product, the HypoxE test®. Further details of the financing round were not disclosed.